Trials / Completed
CompletedNCT02178475
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 943 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (\> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
Conditions
Timeline
- Start date
- 2014-07-18
- Primary completion
- 2016-10-28
- Completion
- 2016-10-28
- First posted
- 2014-06-30
- Last updated
- 2018-07-23
- Results posted
- 2018-07-23
Locations
74 sites across 9 countries: Austria, Belgium, Bulgaria, Czechia, France, Germany, Greece, Poland, Romania
Source: ClinicalTrials.gov record NCT02178475. Inclusion in this directory is not an endorsement.